Novartis Pharma Schweiz AG
Check drug filings and source records for this company-name string.
Listed by the company name as recorded in the source, without merging affiliated entities.
Page reference d601f1d5f9
Drug names46First applicant · distinct drug namesAcceptance records349First applicant · distinct acceptance numbersUnder-review numbers33First applicant · current under-review listCo-applicant records23Subsequent applicant only · separate count
These counts cover loaded acceptance records only. First-applicant and co-applicant counts are not added together. CDE data as of 2026/11/11 06:42.
Drug filings
349 acceptance records as first applicant, grouped into 46 source drug names. Source data as of 2026/11/11 06:42.
Acceptance records are de-duplicated by acceptance number. Drug names are normalized only for width and whitespace; dosage forms and combinations remain separate. Application types are retained from the source. Expand a drug to inspect each record. Published drugs link to their drug pages; other names do not create new public drug pages.
Imatinib Mesylate Tablets 5 records · Latest accepted 2026/11/03
Supplement · 4Import re-registration · 1
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| JYHB2600587 | Supplement | 2026/11/03 | Novartis Pharma Schweiz AG; Novartis Pharma Produktions GmbH | CDE ↗ |
| JYHB2600129 | Supplement | 2026/03/02 | Novartis Pharma Schweiz AG; Novartis Pharma Produktions GmbH; Novartis Pharmaceutical Manufacturing LLC | CDE ↗ |
| JYHB2600126 | Supplement | 2026/03/01 | Novartis Pharma Schweiz AG; Novartis Pharma Produktions GmbH | CDE ↗ |
| JYHZ2300214 | Import re-registration | 2023/05/09 | Novartis Pharma Schweiz AG; Novartis Pharma Produktions GmbH; Beijing Novartis Pharma Co. Ltd. | CDE ↗ |
| JYHB2200412 | Supplement | 2022/08/03 | Novartis Pharma Schweiz AG; Novartis Pharma Produktions GmbH | CDE ↗ |
No verified English name 7 records · Latest accepted 2026/10/23
Supplement · 5Import re-registration · 2
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| JYSB2600291 | Supplement | 2026/10/23 | Novartis Pharma Schweiz AG; Patheon Italia S.p.A. | CDE ↗ |
| JYSZ2600036 | Import re-registration | 2026/07/16 | Novartis Pharma Schweiz AG; Patheon Italia S.p.A.; Beijing Novartis Pharma Co. Ltd. | CDE ↗ |
| JYSB2500308 | Supplement | 2025/12/24 | Novartis Pharma Schweiz AG; Patheon Italia S.p.A. | CDE ↗ |
| JYSB2500305 | Supplement | 2025/12/24 | Novartis Pharma Schweiz AG; Patheon Italia S.p.A. | CDE ↗ |
| JYSB2300109 | Supplement | 2023/06/15 | Novartis Pharma Schweiz AG; Patheon Italia S.p.A. | CDE ↗ |
| JYSZ2200001 | Import re-registration | 2022/01/05 | Novartis Pharma Schweiz AG; Novartis Pharma Stein AG; Beijing Novartis Pharmaceutical Co Ltd | CDE ↗ |
| JYSB2100044 | Supplement | 2021/02/09 | Novartis Pharma Schweiz AG; Novartis Pharma Stein AG | CDE ↗ |
Valsartan and Hydrochlorothiazide Tablets 8 records · Latest accepted 2026/10/10
Import re-registration · 3Supplement · 5
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| JYHZ2600254 | Import re-registration | 2026/10/10 | Novartis Pharma Schweiz AG; Novartis Farma S.p.A. (I) | CDE ↗ |
| JYHB2600285 | Supplement | 2026/06/01 | Novartis Pharma Schweiz AG; Novartis Farma S.p.A. (I) | CDE ↗ |
| JYHZ2100739 | Import re-registration | 2021/12/22 | Novartis Pharma Schweiz AG; Novartis Farma S.p.A.(I) | CDE ↗ |
| JYHZ2100738 | Import re-registration | 2021/12/22 | Novartis Pharma Schweiz AG; Novartis Farma S.p.A.(I) | CDE ↗ |
| JYHB2101347 | Supplement | 2021/08/23 | Novartis Pharma Schweiz AG; Novartis Farma S.p.A.(I) | CDE ↗ |
| JYHB2101346 | Supplement | 2021/08/23 | Novartis Pharma Schweiz AG; Novartis Farma S.p.A.(I) | CDE ↗ |
| JYHB2100204 | Supplement | 2021/03/20 | Novartis Pharma Schweiz AG; Novartis Farma S.p.A.(I) | CDE ↗ |
| JYHB2100203 | Supplement | 2021/03/20 | Novartis Pharma Schweiz AG; Novartis Farma S.p.A.(I) | CDE ↗ |
Nilotinib Capsules 8 records · Latest accepted 2026/09/24
Supplement · 4Import re-registration · 4
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| JYHB2600532 | Supplement | 2026/09/24 | Novartis Pharma Schweiz AG; Novartis Pharma Stein AG; Novartis Pharmaceutical Manufacturing LLC | CDE ↗ |
| JYHZ2600219 | Import re-registration | 2026/09/15 | Novartis Pharma Schweiz AG; Novartis Pharma Stein AG; Novartis Pharmaceutical Manufacturing LLC; Beijing Novartis Pharma Co. Ltd. | CDE ↗ |
| JYHB2600489 | Supplement | 2026/08/24 | Novartis Pharma Schweiz AG; Novartis Pharma Stein AG; Novartis Pharmaceutical Manufacturing LLC | CDE ↗ |
| JYHB2500254 | Supplement | 2025/05/08 | Novartis Pharma Schweiz AG; Novartis Pharma Stein AG; Novartis Pharmaceutical Manufacturing LLC | CDE ↗ |
| JYHB2500253 | Supplement | 2025/05/08 | Novartis Pharma Schweiz AG; Novartis Pharma Stein AG; Novartis Pharmaceutical Manufacturing LLC | CDE ↗ |
| JYHZ2300178 | Import re-registration | 2023/04/11 | Novartis Pharma Schweiz AG; Novartis Pharma Stein AG; Beijing Novartis Pharma Co. Ltd. | CDE ↗ |
| JYHZ2300177 | Import re-registration | 2023/04/11 | Novartis Pharma Schweiz AG; Novartis Pharma Stein AG; Beijing Novartis Pharma Co. Ltd. | CDE ↗ |
| JYHZ2200023 | Import re-registration | 2022/01/21 | Novartis Pharma Schweiz AG; Novartis Pharma Stein AG; Beijing Novartis Pharma Co. Ltd. | CDE ↗ |
No verified English name 3 records · Latest accepted 2026/09/23
Supplement · 2Import · 1
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| JYHB2600534 | Supplement | 2026/09/23 | Novartis Pharma Schweiz AG; AbbVie Ireland NL B.V. | CDE ↗ |
| JYHB2600014 | Supplement | 2026/01/05 | Novartis Pharma Schweiz AG; AbbVie Ireland NL B.V. | CDE ↗ |
| JXHS2400103 | Import | 2024/11/26 | Novartis Pharma Schweiz AG; AbbVie Ireland NL B.V. | CDE ↗ |
No verified English name 7 records · Latest accepted 2026/08/31
Supplement · 4Import · 3
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| JYHB2600497 | Supplement | 2026/08/31 | Novartis Pharma Schweiz AG; Novartis Pharmaceutical Manufacturing LLC | CDE ↗ |
| JXHB2500047 | Supplement | 2025/04/15 | Novartis Pharma Schweiz AG; Novartis Singapore Pharmaceutical Manufacturing Pte. Ltd.; Novartis Pharmaceutical Manufacturing LLC | CDE ↗ |
| JYHB2400575 | Supplement | 2024/10/30 | Novartis Pharma Schweiz AG; Novartis Singapore Pharmaceutical Manufacturing Pte. Ltd.; Novartis Pharmaceutical Manufacturing LLC | CDE ↗ |
| JXHL2400006 | Import | 2024/01/10 | Novartis Pharma Schweiz AG; China Novartis Institutes for BioMedical Research Co. Ltd. | CDE ↗ |
| JXHS2300126 | Import | 2023/12/19 | Novartis Pharma Schweiz AG; Novartis Singapore Pharmaceutical Manufacturing Pte. Ltd.; Beijing Novartis Pharma Co. Ltd. | CDE ↗ |
| JYHB2300341 | Supplement | 2023/06/20 | Novartis Pharma Schweiz AG; Novartis Singapore Pharmaceutical Manufacturing Pte. Ltd.; Lek Pharmaceuticals d.d. | CDE ↗ |
| JXHS2200089 | Import | 2022/09/24 | Novartis Pharma Schweiz AG; Novartis Singapore Pharmaceutical Manufacturing Pte. Ltd.; Beijing Novartis Pharma Co. Ltd. | CDE ↗ |
No verified English name 47 records · Latest accepted 2026/08/20
Supplement · 35Import · 9Import re-registration · 3
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| JYSB2600229 | Supplement | 2026/08/20 | Novartis Pharma Schweiz AG; Novartis Pharma Stein AG | CDE ↗ |
| JYSB2600228 | Supplement | 2026/08/20 | Novartis Pharma Schweiz AG; Novartis Pharma Stein AG | CDE ↗ |
| JYSB2600227 | Supplement | 2026/08/20 | Novartis Pharma Schweiz AG; Novartis Pharma Stein AG; Novartis Pharmaceutical Manufacturing GmbH | CDE ↗ |
| JYSB2500218 | Supplement | 2025/09/16 | Novartis Pharma Schweiz AG; Novartis Pharma Stein AG | CDE ↗ |
| JYSB2500217 | Supplement | 2025/09/16 | Novartis Pharma Schweiz AG; Novartis Pharma Stein AG; Novartis Pharmaceutical Manufacturing GmbH | CDE ↗ |
| JYSB2500216 | Supplement | 2025/09/16 | Novartis Pharma Schweiz AG; Novartis Pharma Stein AG | CDE ↗ |
| JYSB2500187 | Supplement | 2025/08/15 | Novartis Pharma Schweiz AG; Novartis Pharma Stein AG | CDE ↗ |
| JYSB2500186 | Supplement | 2025/08/15 | Novartis Pharma Schweiz AG; Novartis Pharma Stein AG; Novartis Pharmaceutical Manufacturing GmbH | CDE ↗ |
| JYSB2500185 | Supplement | 2025/08/15 | Novartis Pharma Schweiz AG; Novartis Pharma Stein AG | CDE ↗ |
| JXSS2500054 | Import | 2025/05/12 | Novartis Pharma Schweiz AG; Novartis Pharma Stein AG; Novartis Pharmaceutical Manufacturing GmbH; Beijing Novartis Pharma Co. Ltd. | CDE ↗ |
| JYSB2400202 | Supplement | 2024/09/04 | Novartis Pharma Schweiz AG; Novartis Pharma Stein AG | CDE ↗ |
| JYSB2400201 | Supplement | 2024/09/04 | Novartis Pharma Schweiz AG; Novartis Pharma Stein AG; Novartis Pharmaceutical Manufacturing GmbH | CDE ↗ |
| JYSB2400200 | Supplement | 2024/09/04 | Novartis Pharma Schweiz AG; Novartis Pharma Stein AG | CDE ↗ |
| JYSB2400161 | Supplement | 2024/07/17 | Novartis Pharma Schweiz AG; Novartis Pharma Stein AG | CDE ↗ |
| JYSB2400160 | Supplement | 2024/07/17 | Novartis Pharma Schweiz AG; Novartis Pharma Stein AG; Novartis Pharmaceutical Manufacturing GmbH | CDE ↗ |
| JYSB2400159 | Supplement | 2024/07/17 | Novartis Pharma Schweiz AG; Novartis Pharma Stein AG | CDE ↗ |
| JXSS2400049 | Import | 2024/06/21 | Novartis Pharma Schweiz AG; Novartis Pharma Stein AG; Novartis Pharmaceutical Manufacturing GmbH | CDE ↗ |
| JXSS2400048 | Import | 2024/06/21 | Novartis Pharma Schweiz AG; Novartis Pharma Stein AG | CDE ↗ |
| JYSB2400073 | Supplement | 2024/04/03 | Novartis Pharma Schweiz AG; Novartis Pharma Stein AG | CDE ↗ |
| JYSB2400072 | Supplement | 2024/04/03 | Novartis Pharma Schweiz AG; Novartis Pharma Stein AG; Novartis Pharmaceutical Manufacturing GmbH | CDE ↗ |
| JYSB2400033 | Supplement | 2024/02/08 | Novartis Pharma Schweiz AG; Novartis Pharma Stein AG; Novartis Pharmaceutical Manufacturing GmbH | CDE ↗ |
| JYSZ2300028 | Import re-registration | 2023/06/28 | Novartis Pharma Schweiz AG; Novartis Pharma Stein AG; Beijing Novartis Pharma Co. Ltd. | CDE ↗ |
| JYSZ2300027 | Import re-registration | 2023/06/28 | Novartis Pharma Schweiz AG; Novartis Pharma Stein AG; Beijing Novartis Pharma Co. Ltd. | CDE ↗ |
| JYSZ2300026 | Import re-registration | 2023/06/28 | Novartis Pharma Schweiz AG; Novartis Pharma Stein AG; Beijing Novartis Pharma Co. Ltd. | CDE ↗ |
| JYSB2300105 | Supplement | 2023/06/04 | Novartis Pharma Schweiz AG; Novartis Pharma Stein AG | CDE ↗ |
| JYSB2300104 | Supplement | 2023/06/03 | Novartis Pharma Schweiz AG; Novartis Pharma Stein AG | CDE ↗ |
| JYSB2300103 | Supplement | 2023/06/03 | Novartis Pharma Schweiz AG; Novartis Pharma Stein AG | CDE ↗ |
| JYSB2300099 | Supplement | 2023/05/25 | Novartis Pharma Schweiz AG; Novartis Pharma Stein AG | CDE ↗ |
| JYSB2300098 | Supplement | 2023/05/25 | Novartis Pharma Schweiz AG; Novartis Pharma Stein AG | CDE ↗ |
| JYSB2300097 | Supplement | 2023/05/25 | Novartis Pharma Schweiz AG; Novartis Pharma Stein AG | CDE ↗ |
| JXSL2300025 | Import | 2023/01/17 | Novartis Pharma Schweiz AG; Beijing Novartis Pharma Co. Ltd. | CDE ↗ |
| JYSB2300002 | Supplement | 2023/01/06 | Novartis Pharma Schweiz AG; Novartis Pharma Stein AG; Beijing Novartis Pharma Co. Ltd. | CDE ↗ |
| JYSB2300001 | Supplement | 2023/01/06 | Novartis Pharma Schweiz AG; Novartis Pharma Stein AG; Beijing Novartis Pharma Co. Ltd. | CDE ↗ |
| JXSS2200036 | Import | 2022/11/16 | Novartis Pharma Schweiz AG; Novartis Pharma Stein AG; Beijing Novartis Pharma Co. Ltd. | CDE ↗ |
| JXSS2200035 | Import | 2022/11/16 | Novartis Pharma Schweiz AG; Novartis Pharma Stein AG; Beijing Novartis Pharma Co. Ltd. | CDE ↗ |
| JYSB2200202 | Supplement | 2022/10/18 | Novartis Pharma Schweiz AG; Novartis Pharma Stein AG; Sandoz GmbH | CDE ↗ |
| JYSB2200103 | Supplement | 2022/06/21 | Novartis Pharma Schweiz AG; Novartis Pharma Stein AG | CDE ↗ |
| JXSL2200070 | Import | 2022/06/03 | Novartis Pharma Schweiz AG; Beijing Novartis Pharma Co. Ltd. | CDE ↗ |
| JYSB2200049 | Supplement | 2022/03/17 | Novartis Pharma Schweiz AG; Novartis Pharma Stein AG | CDE ↗ |
| JXSL2200011 | Import | 2022/01/25 | Novartis Pharma Schweiz AG; Beijing Novartis Pharma Co. Ltd. | CDE ↗ |
| JYSB2101219 | Supplement | 2021/12/31 | Novartis Pharma Schweiz AG; Novartis Pharma Stein AG | CDE ↗ |
| JYSB2101195 | Supplement | 2021/12/20 | Novartis Pharma Schweiz AG; Novartis Pharma Stein AG | CDE ↗ |
| JYSB2101193 | Supplement | 2021/12/14 | Novartis Pharma Schweiz AG; Novartis Pharma Stein AG | CDE ↗ |
| JXSL2101119 | Import | 2021/10/22 | Novartis Pharma Schweiz AG; Beijing Novartis Pharma Co. Ltd. | CDE ↗ |
| JYSB2101117 | Supplement | 2021/08/31 | Novartis Pharma Schweiz AG; Novartis Pharma Stein AG | CDE ↗ |
| JYSB2101116 | Supplement | 2021/08/31 | Novartis Pharma Schweiz AG; Novartis Pharma Stein AG | CDE ↗ |
| JYSB2101011 | Supplement | 2021/04/19 | Novartis Pharma Schweiz AG; Novartis Pharma Stein AG | CDE ↗ |
No verified English name 4 records · Latest accepted 2026/08/10
Supplement · 3Import · 1
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| JYHB2600445 | Supplement | 2026/08/10 | Novartis Pharma Schweiz AG; Novartis Pharma Stein AG; Novartis Pharmaceutical Manufacturing LLC | CDE ↗ |
| JYHB2600125 | Supplement | 2026/02/28 | Novartis Pharma Schweiz AG; Novartis Pharma Stein AG | CDE ↗ |
| JYHB2500485 | Supplement | 2025/09/12 | Novartis Pharma Schweiz AG; Novartis Pharma Stein AG | CDE ↗ |
| JXHS2400043 | Import | 2024/06/25 | Novartis Pharma Schweiz AG; Novartis Pharma Stein AG; Beijing Novartis Pharma Co. Ltd. | CDE ↗ |
Sacubitril Valsartan Sodium Tablets 30 records · Latest accepted 2026/07/28
Supplement · 24Import re-registration · 6
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| JYHB2600421 | Supplement | 2026/07/28 | Novartis Pharma Schweiz AG; Novartis Farma S.p.A. | CDE ↗ |
| JYHB2600420 | Supplement | 2026/07/28 | Novartis Pharma Schweiz AG; Novartis Farma S.p.A. | CDE ↗ |
| JYHB2600419 | Supplement | 2026/07/28 | Novartis Pharma Schweiz AG; Novartis Farma S.p.A. | CDE ↗ |
| JYHB2600233 | Supplement | 2026/04/24 | Novartis Pharma Schweiz AG; Novartis Farma S.p.A. | CDE ↗ |
| JYHB2600232 | Supplement | 2026/04/24 | Novartis Pharma Schweiz AG; Novartis Farma S.p.A. | CDE ↗ |
| JYHB2600231 | Supplement | 2026/04/24 | Novartis Pharma Schweiz AG; Novartis Farma S.p.A. | CDE ↗ |
| JYHZ2600070 | Import re-registration | 2026/03/27 | Novartis Pharma Schweiz AG; Novartis Farma S.p.A | CDE ↗ |
| JYHZ2600069 | Import re-registration | 2026/03/27 | Novartis Pharma Schweiz AG; Novartis Farma S.p.A | CDE ↗ |
| JYHZ2600068 | Import re-registration | 2026/03/27 | Novartis Pharma Schweiz AG; Novartis Farma S.p.A | CDE ↗ |
| JYHB2600021 | Supplement | 2026/01/07 | Novartis Pharma Schweiz AG; Novartis Farma S.p.A.; Novartis Pharmaceutical Manufacturing LLC | CDE ↗ |
| JYHB2600020 | Supplement | 2026/01/07 | Novartis Pharma Schweiz AG; Novartis Farma S.p.A.; Novartis Pharmaceutical Manufacturing LLC | CDE ↗ |
| JYHB2600019 | Supplement | 2026/01/07 | Novartis Pharma Schweiz AG; Novartis Farma S.p.A.; Novartis Pharmaceutical Manufacturing LLC | CDE ↗ |
| JYHB2400276 | Supplement | 2024/06/12 | Novartis Pharma Schweiz AG; Novartis Farma S.p.A. | CDE ↗ |
| JYHB2400275 | Supplement | 2024/06/12 | Novartis Pharma Schweiz AG; Novartis Farma S.p.A. | CDE ↗ |
| JYHB2400274 | Supplement | 2024/06/12 | Novartis Pharma Schweiz AG; Novartis Farma S.p.A. | CDE ↗ |
| JYHB2300728 | Supplement | 2023/12/16 | Novartis Pharma Schweiz AG; Novartis Farma S.p.A. | CDE ↗ |
| JYHB2300727 | Supplement | 2023/12/16 | Novartis Pharma Schweiz AG; Novartis Farma S.p.A. | CDE ↗ |
| JYHB2300726 | Supplement | 2023/12/16 | Novartis Pharma Schweiz AG; Novartis Farma S.p.A. | CDE ↗ |
| JYHB2300533 | Supplement | 2023/09/16 | Novartis Pharma Schweiz AG; Novartis Farma S.p.A. | CDE ↗ |
| JYHB2300532 | Supplement | 2023/09/16 | Novartis Pharma Schweiz AG; Novartis Farma S.p.A. | CDE ↗ |
| JYHB2300531 | Supplement | 2023/09/16 | Novartis Pharma Schweiz AG; Novartis Farma S.p.A. | CDE ↗ |
| JYHB2101313 | Supplement | 2021/08/12 | Novartis Pharma Schweiz AG; Novartis Farma S.p.A. | CDE ↗ |
| JYHB2101312 | Supplement | 2021/08/12 | Novartis Pharma Schweiz AG; Novartis Farma S.p.A. | CDE ↗ |
| JYHB2101311 | Supplement | 2021/08/12 | Novartis Pharma Schweiz AG; Novartis Farma S.p.A. | CDE ↗ |
| JYHZ2100588 | Import re-registration | 2021/08/05 | Novartis Pharma Schweiz AG; Novartis Singapore Pharmaceutical Manufacturing Private Ltd. | CDE ↗ |
| JYHZ2100587 | Import re-registration | 2021/08/05 | Novartis Pharma Schweiz AG; Novartis Singapore Pharmaceutical Manufacturing Private Ltd. | CDE ↗ |
| JYHZ2100586 | Import re-registration | 2021/08/05 | Novartis Pharma Schweiz AG; Novartis Singapore Pharmaceutical Manufacturing Private Ltd. | CDE ↗ |
| JYHB2101223 | Supplement | 2021/06/30 | Novartis Pharma Schweiz AG; Novartis Singapore Pharmaceutical Manufacturing Private. Ltd. | CDE ↗ |
| JYHB2101222 | Supplement | 2021/06/30 | Novartis Pharma Schweiz AG; Novartis Singapore Pharmaceutical Manufacturing Private. Ltd. | CDE ↗ |
| JYHB2101221 | Supplement | 2021/06/30 | Novartis Pharma Schweiz AG; Novartis Singapore Pharmaceutical Manufacturing Private. Ltd. | CDE ↗ |
Everolimus Tablets 18 records · Latest accepted 2026/07/24
Import re-registration · 4Supplement · 11Import · 3
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| JYHZ2600177 | Import re-registration | 2026/07/24 | Novartis Pharma Schweiz AG; Novartis Pharma Stein AG; Beijing Novartis Pharma Co. Ltd. | CDE ↗ |
| JYHB2500321 | Supplement | 2025/06/14 | Novartis Pharma Schweiz AG; Novartis Pharma Stein AG; Novartis Pharmaceuticals S.R.L. | CDE ↗ |
| JYHB2500320 | Supplement | 2025/06/14 | Novartis Pharma Schweiz AG; Novartis Pharma Stein AG; Novartis Pharmaceuticals S.R.L. | CDE ↗ |
| JYHB2400097 | Supplement | 2024/02/26 | Novartis Pharma Schweiz AG; Novartis Pharma Stein AG | CDE ↗ |
| JYHB2400096 | Supplement | 2024/02/26 | Novartis Pharma Schweiz AG; Novartis Pharma Stein AG | CDE ↗ |
| JYHB2400095 | Supplement | 2024/02/26 | Novartis Pharma Schweiz AG; Novartis Pharma Stein AG | CDE ↗ |
| JYHZ2300167 | Import re-registration | 2023/03/24 | Novartis Pharma Schweiz AG; Novartis Pharma Stein AG; Beijing Novartis Pharma Co. Ltd. | CDE ↗ |
| JYHZ2100716 | Import re-registration | 2021/12/03 | Novartis Pharma Schweiz AG; Novartis Pharma Stein AG; Beijing Novartis Pharma Co. Ltd. | CDE ↗ |
| JYHZ2100715 | Import re-registration | 2021/12/03 | Novartis Pharma Schweiz AG; Novartis Pharma Stein AG; Beijing Novartis Pharma Co. Ltd. | CDE ↗ |
| JYHB2101324 | Supplement | 2021/08/13 | Novartis Pharma Schweiz AG; Novartis Pharma Stein AG | CDE ↗ |
| JYHB2101323 | Supplement | 2021/08/13 | Novartis Pharma Schweiz AG; Novartis Pharma Stein AG | CDE ↗ |
| JYHB2101322 | Supplement | 2021/08/13 | Novartis Pharma Schweiz AG; Novartis Pharma Stein AG | CDE ↗ |
| JXHS2101009 | Import | 2021/04/23 | Novartis Pharma Schweiz AG; Novartis Pharma Stein AG; Beijing Novartis Pharma Co. Ltd. | CDE ↗ |
| JXHS2101008 | Import | 2021/04/23 | Novartis Pharma Schweiz AG; Novartis Pharma Stein AG; Beijing Novartis Pharma Co. Ltd. | CDE ↗ |
| JXHS2101007 | Import | 2021/04/23 | Novartis Pharma Schweiz AG; Novartis Pharma Stein AG; Beijing Novartis Pharma Co. Ltd. | CDE ↗ |
| JYHB2002731 | Supplement | 2021/01/01 | Novartis Pharma Schweiz AG; Novartis Pharma Stein AG | CDE ↗ |
| JYHB2002730 | Supplement | 2021/01/01 | Novartis Pharma Schweiz AG; Novartis Pharma Stein AG | CDE ↗ |
| JYHB2002729 | Supplement | 2021/01/01 | Novartis Pharma Schweiz AG; Novartis Pharma Stein AG | CDE ↗ |
No verified English name 8 records · Latest accepted 2026/07/23
Import re-registration · 2Supplement · 6
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| JYHZ2600176 | Import re-registration | 2026/07/23 | Novartis Pharma Schweiz AG; Novartis Pharma Produktions GmbH | CDE ↗ |
| JYHB2600094 | Supplement | 2026/02/11 | Novartis Pharma Schweiz AG; Novartis Pharma Produktions GmbH | CDE ↗ |
| JYHB2500250 | Supplement | 2025/05/01 | Novartis Pharma Schweiz AG; Novartis Pharma Produktions GmbH; Novartis Saglik Gida ve Tarim Urunleri San.Ve Tic. A.S | CDE ↗ |
| JYHB2400117 | Supplement | 2024/03/08 | Novartis Pharma Schweiz AG; Novartis Pharma Produktions GmbH | CDE ↗ |
| JYHB2200565 | Supplement | 2022/10/20 | Novartis Pharma Schweiz AG; Novartis Pharma Produktions GmbH | CDE ↗ |
| JYHB2200005 | Supplement | 2022/01/10 | Novartis Pharma Schweiz AG; Novartis Pharma Produktions GmbH | CDE ↗ |
| JYHZ2100682 | Import re-registration | 2021/10/29 | Novartis Pharma Schweiz AG; Novartis Pharma Produktions GmbH | CDE ↗ |
| JYHB2100087 | Supplement | 2021/01/22 | Novartis Pharma Schweiz AG; Novartis Pharma Produktions GmbH | CDE ↗ |
Oxcarbazepine Tablets 16 records · Latest accepted 2026/07/20
Import re-registration · 6Supplement · 10
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| JYHZ2600174 | Import re-registration | 2026/07/20 | Novartis Pharma Schweiz AG; Novartis Farma S.p.A.; Beijing Novartis Pharma Co. Ltd. | CDE ↗ |
| JYHZ2600173 | Import re-registration | 2026/07/20 | Novartis Pharma Schweiz AG; Novartis Farma S.p.A.; Beijing Novartis Pharma Co. Ltd. | CDE ↗ |
| JYHB2500573 | Supplement | 2025/10/30 | Novartis Pharma Schweiz AG; Novartis Farma S.p.A | CDE ↗ |
| JYHB2500572 | Supplement | 2025/10/30 | Novartis Pharma Schweiz AG; Novartis Farma S.p.A | CDE ↗ |
| JYHB2500112 | Supplement | 2025/03/05 | Novartis Pharma Schweiz AG; Novartis Farma S.p.A | CDE ↗ |
| JYHB2500111 | Supplement | 2025/03/05 | Novartis Pharma Schweiz AG; Novartis Farma S.p.A | CDE ↗ |
| JYHB2400309 | Supplement | 2024/06/19 | Novartis Pharma Schweiz AG; Novartis Farma S.p.A | CDE ↗ |
| JYHB2400308 | Supplement | 2024/06/19 | Novartis Pharma Schweiz AG; Novartis Farma S.p.A | CDE ↗ |
| JYHB2200334 | Supplement | 2022/06/29 | Novartis Pharma Schweiz AG; Novartis Farma S.p.A | CDE ↗ |
| JYHB2200333 | Supplement | 2022/06/29 | Novartis Pharma Schweiz AG; Novartis Farma S.p.A | CDE ↗ |
| JYHB2200332 | Supplement | 2022/06/29 | Novartis Pharma Schweiz AG; Novartis Farma S.p.A | CDE ↗ |
| JYHB2200331 | Supplement | 2022/06/29 | Novartis Pharma Schweiz AG; Novartis Farma S.p.A | CDE ↗ |
| JYHZ2100686 | Import re-registration | 2021/11/01 | Novartis Pharma Schweiz AG; Novartis Farma S.p.A; Beijing Novartis Pharma Co. Ltd | CDE ↗ |
| JYHZ2100685 | Import re-registration | 2021/11/01 | Novartis Pharma Schweiz AG; Novartis Farma S.p.A; Beijing Novartis Pharma Co. Ltd | CDE ↗ |
| JYHZ2100684 | Import re-registration | 2021/11/01 | Novartis Pharma Schweiz AG; Novartis Farma S.p.A; Beijing Novartis Pharma Co. Ltd | CDE ↗ |
| JYHZ2100683 | Import re-registration | 2021/11/01 | Novartis Pharma Schweiz AG; Novartis Farma S.p.A; Beijing Novartis Pharma Co. Ltd | CDE ↗ |
Pazopanib Tablets 12 records · Latest accepted 2026/07/07
Import re-registration · 3Supplement · 9
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| JYHZ2600162 | Import re-registration | 2026/07/07 | Novartis Pharma Schweiz AG; Siegfried Barbera S.L.; Novartis Pharmaceutical Manufacturing LLC; Beijing Novartis Pharma Co. Ltd. | CDE ↗ |
| JYHB2400518 | Supplement | 2024/10/01 | Novartis Pharma Schweiz AG; Siegfried Barbera S.L.; Novartis Pharmaceutical Manufacturing LLC | CDE ↗ |
| JYHB2200188 | Supplement | 2022/04/08 | Novartis Pharma Schweiz AG; Siegfried Barbera S.L.; Glaxo Operations UK Limited (trading as Glaxo Wellcome Operations) | CDE ↗ |
| JYHB2200187 | Supplement | 2022/04/08 | Novartis Pharma Schweiz AG; Siegfried Barbera S.L.; Glaxo Operations UK Limited (trading as Glaxo Wellcome Operations) | CDE ↗ |
| JYHZ2100622 | Import re-registration | 2021/09/16 | Novartis Pharma Schweiz AG; Glaxo Operations UK Limited (trading as Glaxo Wellcome Operations); Beijing Novartis Pharma Co. Ltd. | CDE ↗ |
| JYHZ2100621 | Import re-registration | 2021/09/16 | Novartis Pharma Schweiz AG; Glaxo Operations UK Limited (trading as Glaxo Wellcome Operations); Beijing Novartis Pharma Co. Ltd. | CDE ↗ |
| JYHB2101244 | Supplement | 2021/07/09 | Novartis Pharma Schweiz AG; Glaxo Operations UK Limited (trading as Glaxo Wellcome Operations) | CDE ↗ |
| JYHB2101243 | Supplement | 2021/07/09 | Novartis Pharma Schweiz AG; Glaxo Operations UK Limited (trading as Glaxo Wellcome Operations) | CDE ↗ |
| JYHB2101057 | Supplement | 2021/04/23 | Novartis Pharma Schweiz AG; Glaxo Operations UK Limited (trading as Glaxo Wellcome Operations) | CDE ↗ |
| JYHB2101056 | Supplement | 2021/04/23 | Novartis Pharma Schweiz AG; Glaxo Operations UK Limited (trading as Glaxo Wellcome Operations) | CDE ↗ |
| JYHB2100035 | Supplement | 2021/01/12 | Novartis Pharma Schweiz AG; Glaxo Operations UK Limited (trading as Glaxo Wellcome Operations) | CDE ↗ |
| JYHB2100034 | Supplement | 2021/01/12 | Novartis Pharma Schweiz AG; Glaxo Operations UK Limited (trading as Glaxo Wellcome Operations) | CDE ↗ |
No verified English name 8 records · Latest accepted 2026/07/06
Supplement · 4Import · 4
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| JYHB2600369 | Supplement | 2026/07/06 | Novartis Pharma Schweiz AG; Novartis Pharma Produktions GmbH | CDE ↗ |
| JYHB2600264 | Supplement | 2026/05/13 | Novartis Pharma Schweiz AG; Novartis Pharma Produktions GmbH | CDE ↗ |
| JYHB2600185 | Supplement | 2026/03/19 | Novartis Pharma Schweiz AG; Novartis Pharma Produktions GmbH | CDE ↗ |
| JYHB2500494 | Supplement | 2025/09/24 | Novartis Pharma Schweiz AG; Novartis Pharma Produktions GmbH | CDE ↗ |
| JXHS2400074 | Import | 2024/09/28 | Novartis Pharma Schweiz AG; Novartis Pharma Produktions GmbH | CDE ↗ |
| JXHS2400061 | Import | 2024/09/05 | Novartis Pharma Schweiz AG; Novartis Pharma Produktions GmbH | CDE ↗ |
| JXHS2400053 | Import | 2024/08/07 | Novartis Pharma Schweiz AG; Novartis Pharma Produktions GmbH; Beijing Novartis Pharma Co. Ltd. | CDE ↗ |
| JXHS2300050 | Import | 2023/06/14 | Novartis Pharma Schweiz AG; Novartis Pharma Produktions GmbH; Beijing Novartis Pharma Co. Ltd. | CDE ↗ |
Eltrombopag Olamine Tablets 14 records · Latest accepted 2026/04/16
Supplement · 10Import re-registration · 2Import · 2
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| JYHB2600219 | Supplement | 2026/04/16 | Novartis Pharma Schweiz AG; Siegfried Barbera S.L.; Novartis Pharmaceutical Manufacturing LLC | CDE ↗ |
| JYHB2500336 | Supplement | 2025/06/25 | Novartis Pharma Schweiz AG; Siegfried Barbera S.L.; Novartis Pharmaceutical Manufacturing LLC | CDE ↗ |
| JYHB2400387 | Supplement | 2024/07/25 | Novartis Pharma Schweiz AG; Siegfried Barbera S.L.; Novartis Pharmaceutical Manufacturing LLC | CDE ↗ |
| JYHB2300197 | Supplement | 2023/03/28 | Novartis Pharma Schweiz AG; Siegfried Barbera S.L.; Lek Pharmaceuticals d.d. | CDE ↗ |
| JYHZ2200159 | Import re-registration | 2022/06/21 | Novartis Pharma Schweiz AG; Glaxo Operations UK Limited (trading as Glaxo Wellcome Operations); Beijing Novartis Pharma Co. Ltd. | CDE ↗ |
| JYHZ2200158 | Import re-registration | 2022/06/21 | Novartis Pharma Schweiz AG; Glaxo Operations UK Limited (trading as Glaxo Wellcome Operations); Beijing Novartis Pharma Co. Ltd. | CDE ↗ |
| JXHS2200044 | Import | 2022/05/24 | Novartis Pharma Schweiz AG; Siegfried Barbera S.L.; Beijing Novartis Pharma Co. Ltd. | CDE ↗ |
| JXHS2200043 | Import | 2022/05/24 | Novartis Pharma Schweiz AG; Siegfried Barbera S.L.; Beijing Novartis Pharma Co. Ltd. | CDE ↗ |
| JYHB2200024 | Supplement | 2022/01/14 | Novartis Pharma Schweiz AG; Glaxo Operations UK Limited (trading as Glaxo Wellcome Operations) | CDE ↗ |
| JYHB2200023 | Supplement | 2022/01/14 | Novartis Pharma Schweiz AG; Glaxo Operations UK Limited (trading as Glaxo Wellcome Operations) | CDE ↗ |
| JYHB2101478 | Supplement | 2021/10/21 | Novartis Pharma Schweiz AG; Glaxo Operations UK Limited (trading as Glaxo Wellcome Operations) | CDE ↗ |
| JYHB2101477 | Supplement | 2021/10/21 | Novartis Pharma Schweiz AG; Glaxo Operations UK Limited (trading as Glaxo Wellcome Operations) | CDE ↗ |
| JYHB2101028 | Supplement | 2021/04/10 | Novartis Pharma Schweiz AG; Glaxo Operations UK Limited (trading as Glaxo Wellcome Operations) | CDE ↗ |
| JYHB2101027 | Supplement | 2021/04/10 | Novartis Pharma Schweiz AG; Glaxo Operations UK Limited (trading as Glaxo Wellcome Operations) | CDE ↗ |
Ciclosporin Soft Capsules 15 records · Latest accepted 2026/04/14
Supplement · 11Import re-registration · 4
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| JYHB2600215 | Supplement | 2026/04/14 | Novartis Pharma Schweiz AG; Catalent Germany Eberbach GmbH | CDE ↗ |
| JYHB2600214 | Supplement | 2026/04/14 | Novartis Pharma Schweiz AG; Catalent Germany Eberbach GmbH | CDE ↗ |
| JYHB2300722 | Supplement | 2023/12/15 | Novartis Pharma Schweiz AG; Catalent Germany Eberbach GmbH | CDE ↗ |
| JYHB2300721 | Supplement | 2023/12/15 | Novartis Pharma Schweiz AG; Catalent Germany Eberbach GmbH | CDE ↗ |
| JYHZ2300072 | Import re-registration | 2023/02/14 | Novartis Pharma Schweiz AG; Catalent Germany Eberbach GmbH; Beijing Novartis Pharma Co. Ltd. | CDE ↗ |
| JYHZ2300071 | Import re-registration | 2023/02/14 | Novartis Pharma Schweiz AG; Catalent Germany Eberbach GmbH; Beijing Novartis Pharma Co. Ltd. | CDE ↗ |
| JYHZ2300070 | Import re-registration | 2023/02/14 | Novartis Pharma Schweiz AG; Catalent Germany Eberbach GmbH; Beijing Novartis Pharma Co. Ltd. | CDE ↗ |
| JYHZ2300069 | Import re-registration | 2023/02/14 | Novartis Pharma Schweiz AG; Catalent Germany Eberbach GmbH; Beijing Novartis Pharma Co. Ltd. | CDE ↗ |
| JYHB2101270 | Supplement | 2021/07/14 | Novartis Pharma Schweiz AG; Catalent Germany Eberbach GmbH | CDE ↗ |
| JYHB2101269 | Supplement | 2021/07/14 | Novartis Pharma Schweiz AG; Catalent Germany Eberbach GmbH | CDE ↗ |
| JYHB2101268 | Supplement | 2021/07/14 | Novartis Pharma Schweiz AG; Catalent Germany Eberbach GmbH | CDE ↗ |
| JYHB2101267 | Supplement | 2021/07/14 | Novartis Pharma Schweiz AG; Catalent Germany Eberbach GmbH | CDE ↗ |
| JYHB2101266 | Supplement | 2021/07/14 | Novartis Pharma Schweiz AG; Catalent Germany Eberbach GmbH | CDE ↗ |
| JYHB2101265 | Supplement | 2021/07/14 | Novartis Pharma Schweiz AG; Catalent Germany Eberbach GmbH | CDE ↗ |
| JYHB2101264 | Supplement | 2021/07/14 | Novartis Pharma Schweiz AG; Catalent Germany Eberbach GmbH | CDE ↗ |
Octreotide Acetate Microspheres for Injection 7 records · Latest accepted 2026/04/04
Supplement · 4Import re-registration · 3
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| JYHB2600205 | Supplement | 2026/04/04 | Novartis Pharma Schweiz AG; Name not romanized; Name not romanized | CDE ↗ |
| JYHB2600204 | Supplement | 2026/04/04 | Novartis Pharma Schweiz AG; Name not romanized; Name not romanized | CDE ↗ |
| JYHB2300525 | Supplement | 2023/09/14 | Novartis Pharma Schweiz AG; Name not romanized; Name not romanized | CDE ↗ |
| JYHB2300524 | Supplement | 2023/09/14 | Novartis Pharma Schweiz AG; Name not romanized; Name not romanized | CDE ↗ |
| JYHZ2200090 | Import re-registration | 2022/03/25 | Novartis Pharma Schweiz AG; Name not romanized; Name not romanized; Beijing Novartis Pharma Co. Ltd. | CDE ↗ |
| JYHZ2200089 | Import re-registration | 2022/03/25 | Novartis Pharma Schweiz AG; Name not romanized; Name not romanized; Beijing Novartis Pharma Co. Ltd. | CDE ↗ |
| JYHZ2200088 | Import re-registration | 2022/03/25 | Novartis Pharma Schweiz AG; Name not romanized; Name not romanized; Beijing Novartis Pharma Co. Ltd. | CDE ↗ |
Ciclosporin Injection 4 records · Latest accepted 2026/03/30
Supplement · 3Import re-registration · 1
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| JYHB2600195 | Supplement | 2026/03/30 | Novartis Pharma Schweiz AG; Novartis Pharma Stein AG | CDE ↗ |
| JYHB2500375 | Supplement | 2025/07/18 | Novartis Pharma Schweiz AG; Novartis Pharma Stein AG | CDE ↗ |
| JYHZ2400069 | Import re-registration | 2024/03/14 | Novartis Pharma Schweiz AG; Novartis Pharma Stein AG; Beijing Novartis Pharma Co. Ltd. | CDE ↗ |
| JYHB2300720 | Supplement | 2023/12/15 | Novartis Pharma Schweiz AG; Novartis Pharma Stein AG | CDE ↗ |
No verified English name 6 records · Latest accepted 2026/03/12
Supplement · 2Import · 4
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| JYHB2600173 | Supplement | 2026/03/12 | Novartis Pharma Schweiz AG; Novartis Pharma Produktions GmbH; Novartis Pharmaceuticals S.R.L. | CDE ↗ |
| JYHB2600172 | Supplement | 2026/03/12 | Novartis Pharma Schweiz AG; Novartis Pharma Produktions GmbH; Novartis Pharmaceuticals S.R.L. | CDE ↗ |
| JXHS2400114 | Import | 2024/12/21 | Novartis Pharma Schweiz AG; Novartis Pharma Produktions GmbH; Beijing Novartis Pharma Co. Ltd. | CDE ↗ |
| JXHS2400113 | Import | 2024/12/21 | Novartis Pharma Schweiz AG; Novartis Pharma Produktions GmbH; Beijing Novartis Pharma Co. Ltd. | CDE ↗ |
| JXHS2300024 | Import | 2023/02/25 | Novartis Pharma Schweiz AG; Novartis Pharma Produktions GmbH; Beijing Novartis Pharma Co. Ltd. | CDE ↗ |
| JXHS2300023 | Import | 2023/02/25 | Novartis Pharma Schweiz AG; Novartis Pharma Produktions GmbH; Beijing Novartis Pharma Co. Ltd. | CDE ↗ |
No verified English name 13 records · Latest accepted 2026/02/10
Import re-registration · 3Supplement · 10
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| JYSZ2600007 | Import re-registration | 2026/02/10 | Novartis Pharma Schweiz AG; Novartis Pharma Stein AG; Name not romanized | CDE ↗ |
| JYSB2600017 | Supplement | 2026/01/16 | Novartis Pharma Schweiz AG; Novartis Manufacturing NV | CDE ↗ |
| JYSB2600016 | Supplement | 2026/01/16 | Novartis Pharma Schweiz AG; Novartis Pharma Stein AG | CDE ↗ |
| JYSB2600008 | Supplement | 2026/01/08 | Novartis Pharma Schweiz AG; Novartis Pharma Stein AG | CDE ↗ |
| JYSB2500256 | Supplement | 2025/10/29 | Novartis Pharma Schweiz AG; Novartis Pharma Stein AG | CDE ↗ |
| JYSB2500035 | Supplement | 2025/02/13 | Novartis Pharma Schweiz AG; Novartis Pharma Stein AG | CDE ↗ |
| JYSB2300087 | Supplement | 2023/05/09 | Novartis Pharma Schweiz AG; Vetter Pharma-Fertigung GmbH & Co. KG; S.A. Alcon-Couvreur N.V. | CDE ↗ |
| JYSB2300066 | Supplement | 2023/04/14 | Novartis Pharma Schweiz AG; Novartis Pharma Stein AG | CDE ↗ |
| JYSB2300065 | Supplement | 2023/04/14 | Novartis Pharma Schweiz AG; Vetter Pharma-Fertigung GmbH & Co. KG | CDE ↗ |
| JYSB2300015 | Supplement | 2023/02/03 | Novartis Pharma Schweiz AG; Novartis Pharma Stein AG | CDE ↗ |
| JYSB2200118 | Supplement | 2022/07/07 | Novartis Pharma Schweiz AG; Novartis Pharma Stein AG | CDE ↗ |
| JYSZ2200031 | Import re-registration | 2022/07/06 | Novartis Pharma Schweiz AG; Vetter Pharma-Fertigung GmbH & Co. KG | CDE ↗ |
| JYSZ2100514 | Import re-registration | 2021/05/10 | Novartis Pharma Schweiz AG; Novartis Pharma Stein AG | CDE ↗ |
No verified English name 2 records · Latest accepted 2026/02/06
Import · 2
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| JXSS2600007 | Import | 2026/02/06 | Novartis Pharma Schweiz AG; Novartis Pharma Stein AG; Beijing Novartis Pharma Co. Ltd. | CDE ↗ |
| JXSS2600006 | Import | 2026/02/06 | Novartis Pharma Schweiz AG; Novartis Pharma Stein AG; Beijing Novartis Pharma Co. Ltd. | CDE ↗ |
No verified English name 16 records · Latest accepted 2025/12/08
Supplement · 14Import re-registration · 2
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| JYHB2500670 | Supplement | 2025/12/08 | Novartis Pharma Schweiz AG; Novartis Pharma Stein AG | CDE ↗ |
| JYHB2500669 | Supplement | 2025/12/08 | Novartis Pharma Schweiz AG; Novartis Pharma Stein AG | CDE ↗ |
| JYHZ2400219 | Import re-registration | 2024/08/09 | Novartis Pharma Schweiz AG; Novartis Pharma Stein AG; Beijing Novartis Pharma Co. Ltd. | CDE ↗ |
| JYHZ2400218 | Import re-registration | 2024/08/09 | Novartis Pharma Schweiz AG; Novartis Pharma Stein AG; Beijing Novartis Pharma Co. Ltd. | CDE ↗ |
| JYHB2400205 | Supplement | 2024/05/10 | Novartis Pharma Schweiz AG; Novartis Pharma Stein AG | CDE ↗ |
| JYHB2400204 | Supplement | 2024/05/10 | Novartis Pharma Schweiz AG; Novartis Pharma Stein AG | CDE ↗ |
| JYHB2400123 | Supplement | 2024/03/13 | Novartis Pharma Schweiz AG; Novartis Pharma Stein AG | CDE ↗ |
| JYHB2400122 | Supplement | 2024/03/13 | Novartis Pharma Schweiz AG; Novartis Pharma Stein AG | CDE ↗ |
| JYHB2300666 | Supplement | 2023/11/20 | Novartis Pharma Schweiz AG; Novartis Pharma Stein AG | CDE ↗ |
| JYHB2300665 | Supplement | 2023/11/20 | Novartis Pharma Schweiz AG; Novartis Pharma Stein AG | CDE ↗ |
| JYHB2300166 | Supplement | 2023/03/08 | Novartis Pharma Schweiz AG; Novartis Pharma Stein AG | CDE ↗ |
| JYHB2300165 | Supplement | 2023/03/08 | Novartis Pharma Schweiz AG; Novartis Pharma Stein AG | CDE ↗ |
| JYHB2200094 | Supplement | 2022/02/21 | Novartis Pharma Schweiz AG; Novartis Pharma Stein AG | CDE ↗ |
| JYHB2200093 | Supplement | 2022/02/21 | Novartis Pharma Schweiz AG; Novartis Pharma Stein AG | CDE ↗ |
| JYHB2101623 | Supplement | 2021/12/29 | Novartis Pharma Schweiz AG; Novartis Pharma Stein AG | CDE ↗ |
| JYHB2101622 | Supplement | 2021/12/29 | Novartis Pharma Schweiz AG; Novartis Pharma Stein AG | CDE ↗ |
No verified English name 3 records · Latest accepted 2025/11/04
Import · 3
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| JXHS2500125 | Import | 2025/11/04 | Novartis Pharma Schweiz AG; Advanced Accelerator Applications (Italy) S.R.L.; Beijing Novartis Pharma Co. Ltd. | CDE ↗ |
| JXHS2500054 | Import | 2025/04/28 | Novartis Pharma Schweiz AG; Advanced Accelerator Applications (Italy) S.R.L.; Beijing Novartis Pharma Co. Ltd. | CDE ↗ |
| JXHS2400095 | Import | 2024/11/13 | Novartis Pharma Schweiz AG; Advanced Accelerator Applications (Italy) S.R.L.; Beijing Novartis Pharma Co. Ltd. | CDE ↗ |
Oxcarbazepine Oral Suspension 5 records · Latest accepted 2025/10/30
Supplement · 4Import re-registration · 1
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| JYHB2500574 | Supplement | 2025/10/30 | Novartis Pharma Schweiz AG; Delpharm Huningue S.A.S. | CDE ↗ |
| JYHB2500114 | Supplement | 2025/03/06 | Novartis Pharma Schweiz AG; Delpharm Huningue S.A.S. | CDE ↗ |
| JYHB2400307 | Supplement | 2024/06/19 | Novartis Pharma Schweiz AG; Delpharm Huningue S.A.S. | CDE ↗ |
| JYHZ2300009 | Import re-registration | 2023/01/05 | Novartis Pharma Schweiz AG; Delpharm Huningue S.A.S.; Beijing Novartis Pharma Co. Ltd. | CDE ↗ |
| JYHB2200387 | Supplement | 2022/07/25 | Novartis Pharma Schweiz AG; Delpharm Huningue S.A.S. | CDE ↗ |
Fingolimod Hydrochloride Capsules 6 records · Latest accepted 2025/09/30
Supplement · 5Import re-registration · 1
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| JYHB2500511 | Supplement | 2025/09/30 | Novartis Pharma Schweiz AG; Novartis Pharma Stein AG | CDE ↗ |
| JYHB2500429 | Supplement | 2025/08/16 | Novartis Pharma Schweiz AG; Novartis Pharma Stein AG; Novartis Pharmaceutical Manufacturing LLC | CDE ↗ |
| JYHB2400595 | Supplement | 2024/11/09 | Novartis Pharma Schweiz AG; Novartis Pharma Stein AG | CDE ↗ |
| JYHZ2300389 | Import re-registration | 2023/10/08 | Novartis Pharma Schweiz AG; Novartis Pharma Stein AG; Beijing Novartis Pharma Co. Ltd. | CDE ↗ |
| JYHB2300451 | Supplement | 2023/08/17 | Novartis Pharma Schweiz AG; Novartis Pharma Stein AG | CDE ↗ |
| JYHB2100123 | Supplement | 2021/02/05 | Novartis Pharma Schweiz AG; Novartis Pharma Stein AG | CDE ↗ |
No verified English name 1 records · Latest accepted 2025/08/02
Import · 1
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| JXSS2500106 | Import | 2025/08/02 | Novartis Pharma Schweiz AG; Novartis Gene Therapies Inc.; Beijing Novartis Pharma Co. Ltd. | CDE ↗ |
No verified English name 1 records · Latest accepted 2025/02/27
Import · 1
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| JXHS2500034 | Import | 2025/02/27 | Novartis Pharma Schweiz AG; Novartis Pharmaceutical Manufacturing LLC; Beijing Novartis Pharma Co. Ltd. | CDE ↗ |
No verified English name 4 records · Latest accepted 2024/12/21
Import · 4
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| JXSS2400112 | Import | 2024/12/21 | Novartis Pharma Schweiz AG; Novartis Pharma Stein AG; Beijing Novartis Pharma Co. Ltd. | CDE ↗ |
| JXSS2400111 | Import | 2024/12/21 | Novartis Pharma Schweiz AG; Alcon-Couvreur N.V.; Beijing Novartis Pharma Co. Ltd. | CDE ↗ |
| JXSS2400089 | Import | 2024/10/12 | Novartis Pharma Schweiz AG; Novartis Pharma Stein AG; Beijing Novartis Pharma Co. Ltd. | CDE ↗ |
| JXSS2400088 | Import | 2024/10/12 | Novartis Pharma Schweiz AG; Alcon-Couvreur N.V.; Beijing Novartis Pharma Co. Ltd. | CDE ↗ |
Indacaterol Maleate and Glycopyrronium Bromide Powder for Inhalation 8 records · Latest accepted 2024/11/29
Import re-registration · 2Supplement · 6
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| JYHZ2400337 | Import re-registration | 2024/11/29 | Novartis Pharma Schweiz AG; Siegfried Barbera S.L.; Beijing Novartis Pharma Co. Ltd. | CDE ↗ |
| JYHZ2400336 | Import re-registration | 2024/11/29 | Novartis Pharma Schweiz AG; Siegfried Barbera S.L.; Beijing Novartis Pharma Co. Ltd. | CDE ↗ |
| JYHB2400606 | Supplement | 2024/11/19 | Novartis Pharma Schweiz AG; Siegfried Barbera S.L. | CDE ↗ |
| JYHB2400605 | Supplement | 2024/11/19 | Novartis Pharma Schweiz AG; Siegfried Barbera S.L. | CDE ↗ |
| JYHB2400278 | Supplement | 2024/06/13 | Novartis Pharma Schweiz AG; Siegfried Barbera S.L. | CDE ↗ |
| JYHB2400277 | Supplement | 2024/06/13 | Novartis Pharma Schweiz AG; Siegfried Barbera S.L. | CDE ↗ |
| JYHB2300340 | Supplement | 2023/06/19 | Novartis Pharma Schweiz AG; Siegfried Barbera S.L. | CDE ↗ |
| JYHB2300339 | Supplement | 2023/06/19 | Novartis Pharma Schweiz AG; Siegfried Barbera S.L. | CDE ↗ |
No verified English name 1 records · Latest accepted 2024/11/13
Import · 1
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| JXHS2400096 | Import | 2024/11/13 | Novartis Pharma Schweiz AG; Advanced Accelerator Applications (Italy) S.r.l; Beijing Novartis Pharma Co. Ltd. | CDE ↗ |
No verified English name 4 records · Latest accepted 2024/06/12
Supplement · 4
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| JXSB2400077 | Supplement | 2024/06/12 | Novartis Pharma Schweiz AG; Novartis Pharma Stein AG | CDE ↗ |
| JXSB2400076 | Supplement | 2024/06/12 | Novartis Pharma Schweiz AG; Alcon-Couvreur N.V. | CDE ↗ |
| JXSB2400041 | Supplement | 2024/04/19 | Novartis Pharma Schweiz AG; Alcon-Couvreur N.V. | CDE ↗ |
| JXSB2400040 | Supplement | 2024/04/19 | Novartis Pharma Schweiz AG; Alcon-Couvreur N.V. | CDE ↗ |
Deferasirox Dispersible Tablets 4 records · Latest accepted 2024/04/12
Import re-registration · 1Supplement · 3
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| JYHZ2400091 | Import re-registration | 2024/04/12 | Novartis Pharma Schweiz AG; Sandoz S.R.L.; Beijing Novartis Pharma Co. Ltd. | CDE ↗ |
| JYHB2200161 | Supplement | 2022/03/29 | Novartis Pharma Schweiz AG; Sandoz S.R.L. | CDE ↗ |
| JYHB2200160 | Supplement | 2022/03/29 | Novartis Pharma Schweiz AG; Sandoz S.R.L. | CDE ↗ |
| JYHB2200159 | Supplement | 2022/03/29 | Novartis Pharma Schweiz AG; Sandoz S.R.L. | CDE ↗ |
Indacaterol Maleate Powder for Inhalation 1 records · Latest accepted 2024/02/19
Supplement · 1
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| JYHB2400086 | Supplement | 2024/02/19 | Novartis Pharma Schweiz AG; Siegfried Barbera S.L. | CDE ↗ |
Valsartan and Amlodipine Tablets（I） 9 records · Latest accepted 2023/11/24
Import re-registration · 1Supplement · 8
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| JYHZ2300441 | Import re-registration | 2023/11/24 | Novartis Pharma Schweiz AG; Siegfried Barbera S.L.; Beijing Novartis Pharma Co. Ltd. | CDE ↗ |
| JYHB2300208 | Supplement | 2023/03/31 | Novartis Pharma Schweiz AG; Novartis Farma S.p.A. | CDE ↗ |
| JYHB2300206 | Supplement | 2023/03/31 | Novartis Pharma Schweiz AG; Novartis Farma S.p.A. | CDE ↗ |
| JYHB2300013 | Supplement | 2023/01/06 | Novartis Pharma Schweiz AG; Siegfried Barbera S.L. | CDE ↗ |
| JYHB2300012 | Supplement | 2023/01/06 | Novartis Pharma Schweiz AG; Siegfried Barbera S.L. | CDE ↗ |
| JYHB2101246 | Supplement | 2021/07/08 | Novartis Pharma Schweiz AG; Novartis Farmaceutica S.A. | CDE ↗ |
| JYHB2101245 | Supplement | 2021/07/08 | Novartis Pharma Schweiz AG; Novartis Farmaceutica S.A. | CDE ↗ |
| JYHB2100048 | Supplement | 2021/01/12 | Novartis Pharma Schweiz AG; Novartis Farmaceutica S.A. | CDE ↗ |
| JYHB2100046 | Supplement | 2021/01/12 | Novartis Pharma Schweiz AG; Novartis Farmaceutica S.A. | CDE ↗ |
Letrozole Tablets 2 records · Latest accepted 2023/08/25
Supplement · 1Import re-registration · 1
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| JYHB2300474 | Supplement | 2023/08/25 | Novartis Pharma Schweiz AG; Novartis Pharma Stein AG; Novartis Farma S.p.A. | CDE ↗ |
| JYHZ2300055 | Import re-registration | 2023/02/03 | Novartis Pharma Schweiz AG; Novartis Pharma Stein AG; Beijing Novartis Pharma Co. Ltd. | CDE ↗ |
Ruxolitinib Phosphate Tablets 17 records · Latest accepted 2023/06/22
Import · 5Supplement · 9Import re-registration · 3
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| JXHS2300054 | Import | 2023/06/22 | Novartis Pharma Schweiz AG; Novartis Pharma Stein AG; Beijing Novartis Pharma Co. Ltd. | CDE ↗ |
| JYHB2200556 | Supplement | 2022/10/13 | Novartis Pharma Schweiz AG; Novartis Pharma Stein AG | CDE ↗ |
| JYHB2200555 | Supplement | 2022/10/13 | Novartis Pharma Schweiz AG; Novartis Pharma Stein AG | CDE ↗ |
| JYHB2200554 | Supplement | 2022/10/13 | Novartis Pharma Schweiz AG; Novartis Pharma Stein AG | CDE ↗ |
| JYHB2200486 | Supplement | 2022/09/05 | Novartis Pharma Schweiz AG; Novartis Pharma Stein AG | CDE ↗ |
| JYHB2200485 | Supplement | 2022/09/05 | Novartis Pharma Schweiz AG; Novartis Pharma Stein AG | CDE ↗ |
| JYHB2200484 | Supplement | 2022/09/05 | Novartis Pharma Schweiz AG; Novartis Pharma Stein AG | CDE ↗ |
| JXHS2200051 | Import | 2022/05/27 | Novartis Pharma Schweiz AG; Novartis Pharma Stein AG; Beijing Novartis Pharma Co. Ltd. | CDE ↗ |
| JXHS2200050 | Import | 2022/05/27 | Novartis Pharma Schweiz AG; Novartis Pharma Stein AG; Beijing Novartis Pharma Co. Ltd. | CDE ↗ |
| JXHS2200049 | Import | 2022/05/27 | Novartis Pharma Schweiz AG; Novartis Pharma Stein AG; Beijing Novartis Pharma Co. Ltd. | CDE ↗ |
| JXHL2101281 | Import | 2021/12/22 | Novartis Pharma Schweiz AG; China Novartis Institutes for BioMedical Research Co. Ltd | CDE ↗ |
| JYHZ2100598 | Import re-registration | 2021/08/09 | Novartis Pharma Schweiz AG; Novartis Pharma Stein AG; Beijing Novartis Pharma Co. Ltd. | CDE ↗ |
| JYHZ2100597 | Import re-registration | 2021/08/09 | Novartis Pharma Schweiz AG; Novartis Pharma Stein AG; Beijing Novartis Pharma Co. Ltd. | CDE ↗ |
| JYHZ2100596 | Import re-registration | 2021/08/09 | Novartis Pharma Schweiz AG; Novartis Pharma Stein AG; Beijing Novartis Pharma Co. Ltd. | CDE ↗ |
| JYHB2002755 | Supplement | 2021/01/01 | Novartis Pharma Schweiz AG; Novartis Pharma Stein AG | CDE ↗ |
| JYHB2002754 | Supplement | 2021/01/01 | Novartis Pharma Schweiz AG; Novartis Pharma Stein AG | CDE ↗ |
| JYHB2002753 | Supplement | 2021/01/01 | Novartis Pharma Schweiz AG; Novartis Pharma Stein AG | CDE ↗ |
Octreotide Acetate Injection 3 records · Latest accepted 2023/05/10
Import re-registration · 1Import · 1Supplement · 1
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| JYHZ2300218 | Import re-registration | 2023/05/10 | Novartis Pharma Schweiz AG; Delpharm Dijon | CDE ↗ |
| JXHS2200103 | Import | 2022/11/05 | Novartis Pharma Schweiz AG; Novartis Pharma Stein AG | CDE ↗ |
| JYHB2101499 | Supplement | 2021/11/02 | Novartis Pharma Schweiz AG; Delpharm Dijon | CDE ↗ |
Glycopyrronium Bromide Powder for Inhalation 2 records · Latest accepted 2023/03/07
Supplement · 2
Metformin Hydrochloride and Vildagliptin Tablets 4 records · Latest accepted 2022/10/20
Supplement · 3Import re-registration · 1
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| JYHB2200566 | Supplement | 2022/10/20 | Novartis Pharma Schweiz AG; Novartis Pharma Produktions GmbH | CDE ↗ |
| JYHB2200004 | Supplement | 2022/01/10 | Novartis Pharma Schweiz AG; Novartis Pharma Produktions GmbH | CDE ↗ |
| JYHZ2100681 | Import re-registration | 2021/10/29 | Novartis Pharma Schweiz AG; Novartis Pharma Produktions GmbH | CDE ↗ |
| JYHB2100086 | Supplement | 2021/01/22 | Novartis Pharma Schweiz AG; Novartis Pharma Produktions GmbH | CDE ↗ |
Zoledronic Acid Injection 2 records · Latest accepted 2022/10/20
Supplement · 1Import re-registration · 1
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| JYHB2200569 | Supplement | 2022/10/20 | Novartis Pharma Schweiz AG; Fresenius Kabi Austria GmbH | CDE ↗ |
| JYHZ2200109 | Import re-registration | 2022/05/07 | Novartis Pharma Schweiz AG; Fresenius Kabi Austria GmbH; Beijing Novartis Pharmaceutical Co Ltd | CDE ↗ |
No verified English name 1 records · Latest accepted 2022/08/18
Import re-registration · 1
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| JYHZ2200229 | Import re-registration | 2022/08/18 | Novartis Pharma Schweiz AG; GlaxoSmithKline Manufacturing S.P.A.; Name not romanized | CDE ↗ |
No verified English name 1 records · Latest accepted 2021/10/22
Import · 1
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| JXHS2101062 | Import | 2021/10/22 | Novartis Pharma Schweiz AG; Novartis Singapore Pharmaceutical Manufacturing Pte. Ltd.; Beijing Novartis Pharma Co. Ltd. | CDE ↗ |
No verified English name 2 records · Latest accepted 2021/07/30
Import re-registration · 1Supplement · 1
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| JYHZ2100579 | Import re-registration | 2021/07/30 | Novartis Pharma Schweiz AG; Wasserburger Arzneimittelwerk GmbH; Beijing Novartis Pharma Co. Ltd. | CDE ↗ |
| JYHB2100201 | Supplement | 2021/03/20 | Novartis Pharma Schweiz AG; Wasserburger Arzneimittelwerk GmbH | CDE ↗ |
Valsartan and Amlodipine Tablets 4 records · Latest accepted 2021/07/08
Supplement · 4
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| JYHB2101248 | Supplement | 2021/07/08 | Novartis Pharma Schweiz AG; Novartis Farmaceutica S.A. | CDE ↗ |
| JYHB2101247 | Supplement | 2021/07/08 | Novartis Pharma Schweiz AG; Novartis Farmaceutica S.A. | CDE ↗ |
| JYHB2100049 | Supplement | 2021/01/12 | Novartis Pharma Schweiz AG; Novartis Farmaceutica S.A. | CDE ↗ |
| JYHB2100047 | Supplement | 2021/01/12 | Novartis Pharma Schweiz AG; Novartis Farmaceutica S.A. | CDE ↗ |
Ondansetron Hydrochloride Injection 5 records · Latest accepted 2021/05/31
Supplement · 5
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| JYHB2101155 | Supplement | 2021/05/31 | Novartis Pharma Schweiz AG; Sandoz Manufacturing Inc. | CDE ↗ |
| JYHB2101121 | Supplement | 2021/05/21 | Novartis Pharma Schweiz AG; GlaxoSmithKline Manufacturing S.p.A | CDE ↗ |
| JYHB2101120 | Supplement | 2021/05/21 | Novartis Pharma Schweiz AG; GlaxoSmithKline Manufacturing S.p.A | CDE ↗ |
| JYHB2100133 | Supplement | 2021/02/09 | Novartis Pharma Schweiz AG; Sandoz Manufacturing Inc. | CDE ↗ |
| JYHB2100132 | Supplement | 2021/02/09 | Novartis Pharma Schweiz AG; Sandoz Manufacturing Inc. | CDE ↗ |
Emedastine Difumarate Eye Drops 1 records · Latest accepted 2021/01/14
Supplement · 1
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| JYHB2100058 | Supplement | 2021/01/14 | Novartis Pharma Schweiz AG; S.A. Alcon-Couvreur N.V. | CDE ↗ |
Changes in the last 90 days
11 events from 2026/08/14 to 2026/11/11. CDE data as of 2026/11/11 06:42; NMPA data as of 2026/11/10 18:31.
This source was last successfully updated at 2026/11/10 18:31; current coverage may be incomplete.
Last 90 days, ordered by fact date. Marketing approvals, trial registrations, supplements, notices and review changes are labelled separately. Fact dates are approval dates, acceptance dates, trial first-publication dates or complete-snapshot observation dates, as applicable. Publication and site-observation dates are separate. Historical backfills are not current-period new events. Exit records cover currently inactive applications with an identifiable complete snapshot, not a full review history.
Accepted: 11 applications
- 2026/11/03Accepted
Imatinib Mesylate Tablets
JYHB2600587
Fact date: 2026/11/03 · Site observation date: 2026/11/04
View source ↗ - 2026/10/23Accepted
No verified English name
JYSB2600291
Fact date: 2026/10/23 · Site observation date: 2026/10/24
View source ↗ - 2026/10/10Accepted
Valsartan and Hydrochlorothiazide Tablets
JYHZ2600254
Fact date: 2026/10/10 · Site observation date: 2026/10/22
View source ↗ - 2026/09/24Accepted
Nilotinib Capsules
JYHB2600532
Fact date: 2026/09/24 · Site observation date: 2026/10/22
View source ↗ - 2026/09/23Accepted
No verified English name
JYHB2600534
Fact date: 2026/09/23 · Site observation date: 2026/10/22
View source ↗ - 2026/09/15Accepted
Nilotinib Capsules
JYHZ2600219
Fact date: 2026/09/15 · Site observation date: 2026/10/22
View source ↗ - 2026/08/31Accepted
No verified English name
JYHB2600497
Fact date: 2026/08/31 · Site observation date: 2026/10/22
View source ↗ - 2026/08/24Accepted
Nilotinib Capsules
JYHB2600489
Fact date: 2026/08/24 · Site observation date: 2026/10/22
View source ↗ - 2026/08/20Accepted
No verified English name
JYSB2600229
Fact date: 2026/08/20 · Site observation date: 2026/10/22
View source ↗ - 2026/08/20Accepted
No verified English name
JYSB2600228
Fact date: 2026/08/20 · Site observation date: 2026/10/22
View source ↗ - 2026/08/20Accepted
No verified English name
JYSB2600227
Fact date: 2026/08/20 · Site observation date: 2026/10/22
View source ↗
Under review
33 acceptance numbers with this company as first applicant are currently listed as under review by CDE. Source data as of 2026/11/11 06:42.
| Drug | Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|---|
| Imatinib Mesylate Tablets | JYHB2600587 | Supplement | 2026/11/03 | Novartis Pharma Schweiz AG; Novartis Pharma Produktions GmbH | CDE ↗ |
| No verified English name | JYSB2600291 | Supplement | 2026/10/23 | Novartis Pharma Schweiz AG; Patheon Italia S.p.A. | CDE ↗ |
| Valsartan and Hydrochlorothiazide Tablets | JYHZ2600254 | Import re-registration | 2026/10/10 | Novartis Pharma Schweiz AG; Novartis Farma S.p.A. (I) | CDE ↗ |
| Nilotinib Capsules | JYHB2600532 | Supplement | 2026/09/24 | Novartis Pharma Schweiz AG; Novartis Pharma Stein AG; Novartis Pharmaceutical Manufacturing LLC | CDE ↗ |
| No verified English name | JYHB2600534 | Supplement | 2026/09/23 | Novartis Pharma Schweiz AG; AbbVie Ireland NL B.V. | CDE ↗ |
| Nilotinib Capsules | JYHZ2600219 | Import re-registration | 2026/09/15 | Novartis Pharma Schweiz AG; Novartis Pharma Stein AG; Novartis Pharmaceutical Manufacturing LLC; Beijing Novartis Pharma Co. Ltd. | CDE ↗ |
| No verified English name | JYHB2600497 | Supplement | 2026/08/31 | Novartis Pharma Schweiz AG; Novartis Pharmaceutical Manufacturing LLC | CDE ↗ |
| Nilotinib Capsules | JYHB2600489 | Supplement | 2026/08/24 | Novartis Pharma Schweiz AG; Novartis Pharma Stein AG; Novartis Pharmaceutical Manufacturing LLC | CDE ↗ |
| No verified English name | JYSB2600229 | Supplement | 2026/08/20 | Novartis Pharma Schweiz AG; Novartis Pharma Stein AG | CDE ↗ |
| No verified English name | JYSB2600228 | Supplement | 2026/08/20 | Novartis Pharma Schweiz AG; Novartis Pharma Stein AG | CDE ↗ |
| No verified English name | JYSB2600227 | Supplement | 2026/08/20 | Novartis Pharma Schweiz AG; Novartis Pharma Stein AG; Novartis Pharmaceutical Manufacturing GmbH | CDE ↗ |
| No verified English name | JYHB2600445 | Supplement | 2026/08/10 | Novartis Pharma Schweiz AG; Novartis Pharma Stein AG; Novartis Pharmaceutical Manufacturing LLC | CDE ↗ |
| Sacubitril Valsartan Sodium Tablets | JYHB2600421 | Supplement | 2026/07/28 | Novartis Pharma Schweiz AG; Novartis Farma S.p.A. | CDE ↗ |
| Sacubitril Valsartan Sodium Tablets | JYHB2600420 | Supplement | 2026/07/28 | Novartis Pharma Schweiz AG; Novartis Farma S.p.A. | CDE ↗ |
| Sacubitril Valsartan Sodium Tablets | JYHB2600419 | Supplement | 2026/07/28 | Novartis Pharma Schweiz AG; Novartis Farma S.p.A. | CDE ↗ |
| Everolimus Tablets | JYHZ2600177 | Import re-registration | 2026/07/24 | Novartis Pharma Schweiz AG; Novartis Pharma Stein AG; Beijing Novartis Pharma Co. Ltd. | CDE ↗ |
| No verified English name | JYHZ2600176 | Import re-registration | 2026/07/23 | Novartis Pharma Schweiz AG; Novartis Pharma Produktions GmbH | CDE ↗ |
| Oxcarbazepine Tablets | JYHZ2600174 | Import re-registration | 2026/07/20 | Novartis Pharma Schweiz AG; Novartis Farma S.p.A.; Beijing Novartis Pharma Co. Ltd. | CDE ↗ |
| Oxcarbazepine Tablets | JYHZ2600173 | Import re-registration | 2026/07/20 | Novartis Pharma Schweiz AG; Novartis Farma S.p.A.; Beijing Novartis Pharma Co. Ltd. | CDE ↗ |
| No verified English name | JYSZ2600036 | Import re-registration | 2026/07/16 | Novartis Pharma Schweiz AG; Patheon Italia S.p.A.; Beijing Novartis Pharma Co. Ltd. | CDE ↗ |
| Pazopanib Tablets | JYHZ2600162 | Import re-registration | 2026/07/07 | Novartis Pharma Schweiz AG; Siegfried Barbera S.L.; Novartis Pharmaceutical Manufacturing LLC; Beijing Novartis Pharma Co. Ltd. | CDE ↗ |
| No verified English name | JYHB2600369 | Supplement | 2026/07/06 | Novartis Pharma Schweiz AG; Novartis Pharma Produktions GmbH | CDE ↗ |
| No verified English name | JYHB2600264 | Supplement | 2026/05/13 | Novartis Pharma Schweiz AG; Novartis Pharma Produktions GmbH | CDE ↗ |
| No verified English name | JYHB2600173 | Supplement | 2026/03/12 | Novartis Pharma Schweiz AG; Novartis Pharma Produktions GmbH; Novartis Pharmaceuticals S.R.L. | CDE ↗ |
| No verified English name | JYHB2600172 | Supplement | 2026/03/12 | Novartis Pharma Schweiz AG; Novartis Pharma Produktions GmbH; Novartis Pharmaceuticals S.R.L. | CDE ↗ |
| Imatinib Mesylate Tablets | JYHB2600129 | Supplement | 2026/03/02 | Novartis Pharma Schweiz AG; Novartis Pharma Produktions GmbH; Novartis Pharmaceutical Manufacturing LLC | CDE ↗ |
| No verified English name | JXSS2600007 | Import | 2026/02/06 | Novartis Pharma Schweiz AG; Novartis Pharma Stein AG; Beijing Novartis Pharma Co. Ltd. | CDE ↗ |
| No verified English name | JXSS2600006 | Import | 2026/02/06 | Novartis Pharma Schweiz AG; Novartis Pharma Stein AG; Beijing Novartis Pharma Co. Ltd. | CDE ↗ |
| Sacubitril Valsartan Sodium Tablets | JYHB2600021 | Supplement | 2026/01/07 | Novartis Pharma Schweiz AG; Novartis Farma S.p.A.; Novartis Pharmaceutical Manufacturing LLC | CDE ↗ |
| Sacubitril Valsartan Sodium Tablets | JYHB2600020 | Supplement | 2026/01/07 | Novartis Pharma Schweiz AG; Novartis Farma S.p.A.; Novartis Pharmaceutical Manufacturing LLC | CDE ↗ |
| Sacubitril Valsartan Sodium Tablets | JYHB2600019 | Supplement | 2026/01/07 | Novartis Pharma Schweiz AG; Novartis Farma S.p.A.; Novartis Pharmaceutical Manufacturing LLC | CDE ↗ |
| No verified English name | JYSB2500256 | Supplement | 2025/10/29 | Novartis Pharma Schweiz AG; Novartis Pharma Stein AG | CDE ↗ |
| Fingolimod Hydrochloride Capsules | JYHB2500429 | Supplement | 2025/08/16 | Novartis Pharma Schweiz AG; Novartis Pharma Stein AG; Novartis Pharmaceutical Manufacturing LLC | CDE ↗ |
Catalogue holder records
32 loaded active catalogue records whose holder name matches this source company name. Source data as of 2026/11/11 06:38. Manufacturer-only records are excluded.
| Drug | Marketing authorization holder | Manufacturer | Approval number | Approved | Catalogue category (source text) | View source |
|---|---|---|---|---|---|---|
| No verified English name | Novartis Pharma Schweiz AG | Novartis Pharma Stein AG | 国药准字HJ20250056 | 2025/05/13 | Imported originator drug | CDE ↗ |
| Glycopyrronium Bromide Powder for Inhalation, Hard Capsules | Novartis Pharma Schweiz AG | Novartis Pharma Stein AG | H20180002;H20180003 | 2018/04/16 | Imported originator drug | CDE ↗ |
| Sacubitril Valsartan Sodium Tablets | Novartis Pharma Schweiz AG | Novartis Singapore Pharmaceutical Manufacturing Private.Ltd. | H20170364 | 2017/09/20 | Imported originator drug | CDE ↗ |
| Sacubitril Valsartan Sodium Tablets | Novartis Pharma Schweiz AG | Novartis Singapore Pharmaceutical Manufacturing Private.Ltd. | H20170363 | 2017/09/20 | Imported originator drug | CDE ↗ |
| Sacubitril Valsartan Sodium Tablets | Novartis Pharma Schweiz AG | Novartis Singapore Pharmaceutical Manufacturing Private.Ltd. | H20170362 | 2017/09/20 | Imported originator drug | CDE ↗ |
| Sacubitril Valsartan Sodium Tablets | Novartis Pharma Schweiz AG | Novartis Pharma Stein AG | H20170342 | 2017/07/26 | Imported originator drug | CDE ↗ |
| Sacubitril Valsartan Sodium Tablets | Novartis Pharma Schweiz AG | Novartis Pharma Stein AG | H20170343;国药准字J20171054 | 2017/07/26 | Imported originator drug | CDE ↗ |
| Sacubitril Valsartan Sodium Tablets | Novartis Pharma Schweiz AG | Novartis Pharma Stein AG | H20170344 | 2017/07/26 | Imported originator drug | CDE ↗ |
| Pazopanib Tablets | Novartis Pharma Schweiz AG | Glaxo Operations UK Limited (trading as Glaxo Wellcome Operations) | H20170062 | 2017/02/21 | Imported originator drug | CDE ↗ |
| No verified English name | Novartis Pharma Schweiz AG | Novartis Pharma Produktions GmbH | H20171034 | 2014/12/09 | Imported originator drug | CDE ↗ |
| Everolimus Tablets | Novartis Pharma Schweiz AG | Novartis Pharma Stein AG | H20150093 | 2014/02/13 | Imported originator drug | CDE ↗ |
| Everolimus Tablets | Novartis Pharma Schweiz AG | Novartis Pharma Stein AG | H20171145 | 2013/01/22 | Imported originator drug | CDE ↗ |
| Valsartan and Amlodipine Tablets | Novartis Pharma Schweiz AG | Novartis Farmaceutica SA | H20171190;H20171191 | 2012/10/11 | Imported originator drug | CDE ↗ |
| Indacaterol Maleate Powder for Inhalation | Novartis Pharma Schweiz AG | Novartis Pharma Stein AG | H20160302 | 2012/06/15 | Imported originator drug | CDE ↗ |
| Deferasirox Dispersible Tablets | Novartis Pharma Schweiz AG | Novartis Pharma Stein AG | H20150208 | 2010/06/12 | Imported originator drug | CDE ↗ |
| Valsartan and Amlodipine Tablets（I） | Novartis Pharma Schweiz AG | Novartis Farmaceutica S.A. | H20150310;H20150311 | 2009/09/29 | Imported originator drug | CDE ↗ |
| Zoledronic Acid Concentrated Solution for Injection | Novartis Pharma Schweiz AG | Novartis Pharma Stein AG | H20150049 | 2008/11/04 | Imported originator drug | CDE ↗ |
| Zoledronic Acid Injection | Novartis Pharma Schweiz AG | Fresenius Kabi Austria GmbH | H20181132 | 2007/04/26 | Imported originator drug | CDE ↗ |
| Imatinib Mesylate Tablets | Novartis Pharma Schweiz AG | Novartis Pharma Produktions GmbH | H20150112 | 2005/01/04 | Imported originator drug | CDE ↗ |
| Imatinib Mesylate Tablets | Novartis Pharma Schweiz AG | Novartis Pharma Stein AG | H20150298 | 2005/01/04 | Imported originator drug | CDE ↗ |
| Valsartan and Hydrochlorothiazide Tablets | Novartis Pharma Schweiz AG | Novartis Farma S.p.A.(I) | H20150055 | 2004/10/21 | Imported originator drug | CDE ↗ |
| Octreotide Acetate Microspheres for Injection | Novartis Pharma Schweiz AG | Name not romanized | H20171262 | 2003/08/15 | Imported originator drug | CDE ↗ |
| Octreotide Acetate Microspheres for Injection | Novartis Pharma Schweiz AG | Name not romanized | H20171261 | 2003/08/15 | Imported originator drug | CDE ↗ |
| Oxcarbazepine Tablets | Novartis Pharma Schweiz AG | Novartis Farma S.p.A. | H20171030;H20171031 | 2003/06/20 | Imported originator drug | CDE ↗ |
| Imatinib Mesylate Capsules | Novartis Pharma Schweiz AG | Novartis Pharma Stein AG | H20150294 | 2002/04/17 | Imported originator drug | CDE ↗ |
| Ciclosporin Soft Capsules | Novartis Pharma Schweiz AG | Catalent Germany Eberbach GmbH | H20140287;H20140291 | 2002/03/06 | Imported originator drug | CDE ↗ |
| Letrozole Tablets | Novartis Pharma Schweiz AG | Novartis Pharma Stein AG | H20140149 | 2001/07/20 | Imported originator drug | CDE ↗ |
| Oxcarbazepine Tablets | Novartis Pharma Schweiz AG | Novartis Farma S.p.A. | H20171032;H20171033 | 1997/12/05 | Imported originator drug | CDE ↗ |
| Ciclosporin Soft Capsules | Novartis Pharma Schweiz AG | Catalent Germany Eberbach GmbH | H20140290;H20140293 | 1997/05/31 | Imported originator drug | CDE ↗ |
| Octreotide Acetate Injection | Novartis Pharma Schweiz AG | Novartis Pharma Stein AG | H20150364 | 1996/01/15 | Imported originator drug | CDE ↗ |
| Ciclosporin Soft Capsules | Novartis Pharma Schweiz AG | Catalent Germany Eberbach GmbH | H20140288;H20140292 | 1994/05/27 | Imported originator drug | CDE ↗ |
| Baclofen Tablets | Novartis Pharma Schweiz AG | Novartis Farma S.p.A | H20140326 | 1994/05/06 | Imported originator drug | CDE ↗ |
Only active catalogue records matching the source holder name are listed. A manufacturer role does not count as a holder record. The catalogue covers only part of the chemical-drug market; source categories do not establish complete market coverage or qualifications.
API registrations
5 loaded active API registrations whose first registered company matches this source company name. Source data as of 2026/11/11 06:40.
| Name | Company / applicant | Registration number | Status | Source update date | View source |
|---|---|---|---|---|---|
| No verified English name | Novartis Pharma Schweiz AG | Y20190009990 | A | — | CDE ↗ |
| No verified English name | Novartis Pharma Schweiz AG | Y20190009149 | A | — | CDE ↗ |
| No verified English name | Novartis Pharma Schweiz AG | Y20190009107 | A | 2024/10/17 | CDE ↗ |
| No verified English name | Novartis Pharma Schweiz AG | Y20180001271 | A | 2026/01/17 | CDE ↗ |
| No verified English name | Novartis Pharma Schweiz AG | Y20170001980 | A | 2023/03/24 | CDE ↗ |
Only loaded active API registrations not listed as cancelled are shown. A/I are source registration statuses. Records are listed by registration number and do not establish capacity or supply. The register does not identify the associated formulation.
Co-applicant records
23 acceptance records name this company after the first applicant. They are listed separately and are not included in first-applicant drug or filing counts. Source data as of 2026/11/11 06:42.
| Drug | Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|---|
| No verified English name | JTS2600172 | Import | 2026/11/05 | Novartis Pharmaceutical Manufacturing GmbH; Novartis Pharma Schweiz AG; Beijing Nuo Hua Pharmaceutical Co., Ltd. romanized | CDE ↗ |
| Deferasirox Dispersible Tablets | JTH2600223 | Import | 2026/10/26 | Novartis Pharmaceuticals S.R.L.; Novartis Pharma Schweiz AG; Beijing Nuo Hua Pharmaceutical Co., Ltd. romanized | CDE ↗ |
| No verified English name | JTH2600219 | Import | 2026/10/21 | Novartis Pharmaceutical Manufacturing LLC; Novartis Pharma Schweiz AG; Beijing Nuo Hua Pharmaceutical Co., Ltd. romanized | CDE ↗ |
| No verified English name | JTH2600195 | Not stated by source | 2026/09/16 | Novartis Pharmaceuticals S.R.L.; Novartis Pharma Schweiz AG; Beijing Nuo Hua Pharmaceutical Co., Ltd. romanized | CDE ↗ |
| No verified English name | JTH2600194 | Not stated by source | 2026/09/16 | Novartis Pharmaceuticals S.R.L.; Novartis Pharma Schweiz AG; Beijing Nuo Hua Pharmaceutical Co., Ltd. romanized | CDE ↗ |
| No verified English name | JTH2600146 | Not stated by source | 2026/07/15 | Novartis Pharmaceutical Manufacturing LLC; Novartis Pharma Schweiz AG; Beijing Nuo Hua Pharmaceutical Co., Ltd. romanized | CDE ↗ |
| No verified English name | JTH2600145 | Not stated by source | 2026/07/15 | Advanced Accelerator Applications (Italy) S.R.L.; Novartis Pharma Schweiz AG; Beijing Nuo Hua Pharmaceutical Co., Ltd. romanized | CDE ↗ |
| No verified English name | JTH2600144 | Not stated by source | 2026/07/15 | Advanced Accelerator Applications (Italy) S.R.L.; Novartis Pharma Schweiz AG; Beijing Nuo Hua Pharmaceutical Co., Ltd. romanized | CDE ↗ |
| No verified English name | JTH2600143 | Not stated by source | 2026/07/15 | Advanced Accelerator Applications (Italy) S.R.L.; Novartis Pharma Schweiz AG; Beijing Nuo Hua Pharmaceutical Co., Ltd. romanized | CDE ↗ |
| No verified English name | JTH2600113 | Not stated by source | 2026/06/18 | AbbVie Ireland NL B.V.; Novartis Pharma Schweiz AG; Beijing Nuo Hua Pharmaceutical Co., Ltd. romanized | CDE ↗ |
| No verified English name | JTH2600096 | Not stated by source | 2026/05/22 | Novartis Pharmaceutical Manufacturing LLC; Novartis Pharma Schweiz AG; Beijing Nuo Hua Pharmaceutical Co., Ltd. romanized | CDE ↗ |
| No verified English name | JTS2600078 | Not stated by source | 2026/05/08 | Novartis Pharmaceutical Manufacturing GmbH; Novartis Pharma Schweiz AG; Beijing Nuo Hua Pharmaceutical Co., Ltd. romanized | CDE ↗ |
| Ciclosporin Injection | JTH2600055 | Not stated by source | 2026/03/13 | Delpharm Dijon; Novartis Pharma Schweiz AG; Beijing Nuo Hua Pharmaceutical Co., Ltd. romanized | CDE ↗ |
| No verified English name | JTS2600005 | Not stated by source | 2026/01/06 | Novartis Pharmaceutical Manufacturing GmbH; Novartis Pharma Schweiz AG; Beijing Nuo Hua Pharmaceutical Co., Ltd. romanized | CDE ↗ |
| No verified English name | JTS2600004 | Not stated by source | 2026/01/06 | Novartis Pharma Stein AG; Novartis Pharma Schweiz AG; Beijing Nuo Hua Pharmaceutical Co., Ltd. romanized | CDE ↗ |
| No verified English name | JTH2600002 | Not stated by source | 2026/01/06 | Novartis Pharma Stein AG; Novartis Pharma Schweiz AG; Beijing Nuo Hua Pharmaceutical Co., Ltd. romanized | CDE ↗ |
| No verified English name | JTH2600001 | Not stated by source | 2026/01/06 | Novartis Pharma Stein AG; Novartis Pharma Schweiz AG; Beijing Nuo Hua Pharmaceutical Co., Ltd. romanized | CDE ↗ |
| No verified English name | JTH2500193 | Not stated by source | 2025/12/16 | Novartis Pharmaceutical Manufacturing LLC; Novartis Pharma Schweiz AG; Beijing Nuo Hua Pharmaceutical Co., Ltd. romanized | CDE ↗ |
| No verified English name | JTH2500192 | Not stated by source | 2025/12/13 | Novartis Pharmaceutical Manufacturing LLC; Novartis Pharma Schweiz AG; Beijing Nuo Hua Pharmaceutical Co., Ltd. romanized | CDE ↗ |
| No verified English name | JTH2500189 | Not stated by source | 2025/12/09 | Novartis Pharma Produktions GmbH; Novartis Pharma Schweiz AG; Beijing Nuo Hua Pharmaceutical Co., Ltd. romanized | CDE ↗ |
| No verified English name | JTS2500039 | Not stated by source | 2025/06/06 | Novartis Gene Therapies Inc.; Novartis Pharma Schweiz AG; Beijing Nuo Hua Pharmaceutical Co., Ltd. romanized | CDE ↗ |
| No verified English name | JTS2500038 | Not stated by source | 2025/06/06 | Novartis Gene Therapies Inc.; Novartis Pharma Schweiz AG; Beijing Nuo Hua Pharmaceutical Co., Ltd. romanized | CDE ↗ |
| No verified English name | JTH2100547 | Not stated by source | 2021/06/10 | Novartis Singapore Pharmaceutical Manufacturing Pte. Ltd.; Novartis Pharma Schweiz AG; Beijing Nuo Hua Pharmaceutical Co., Ltd. romanized | CDE ↗ |
How current is each source?
- CDE acceptances and review
- Last successful update: 2026/11/11 06:42
- Chemical-drug catalogue
- Last successful update: 2026/11/11 06:38
- Full API register
- Last successful update: 2026/11/11 06:40
- NMPA drug delivery notices
- Last successful update: 2026/11/10 18:31 · Current coverage may be incomplete
First index-page publication dates: — to —; 0 pages pending. Covers loaded notices only, not a complete historical approval database.
Listed by the company name as recorded in the source, without merging affiliated entities.
This page summarizes loaded records only, without new source queries or collection. Parent companies, subsidiaries, former names and aliases are not merged. Counts from different sources must not be added together. No loaded record does not establish the absence of a filing or registration. Check original records where coverage is incomplete, an update has failed, or a source lies outside the loaded scope.
Fact dates are approval dates, acceptance dates, trial first-publication dates or complete-snapshot observation dates, as applicable. Publication and site-observation dates are separate. Historical backfills are not current-period new events. Exit records cover currently inactive applications with an identifiable complete snapshot, not a full review history.
Drug names use verified official English names only. Missing names are shown as No verified English name, linking to a Chinese page. Company labels use verified official names, Latin source names, then fixed-rule transliterations marked romanized. Original statutory reference numbers are the sole visible Chinese exception.
Legal reference identifiers are retained verbatim. Company labels use official English entries where available, or a visibly marked fixed romanization. Chinese free text is not displayed; use the source links or source-name columns in CSV exports.